Avid Bioservices Inc (CDMO)

[cjgaddy]

Dr. Thorpe presenting PGN635 (Fully-human Bavi) as Imaging Agent on 2-4-2013 at “SPIE BIOS Photonics West” in SanFran…

Feb2-7 2013: “SPIE BIOS Photonics West”, SanFran
SPIE = Society of Photographic Instrumentation Engineers
“SPIE, the Intl. Society For Optics & Photonics, is a non-profit scientific society which publishes research papers & books, organizes world-class scientific conferences, and provides educational opportunities for scientists & engineers.”
- - - - - -
SPIE Photonics West 2013 - Attend the most influential conference for biophotonics and biomedical optics, industrial lasers & high-power laser manufacturing, optoelectronics, microfabrication, and green photonics.
4,200 papers * 18 plenary presentations * 70 special events * 65 courses * two world-class exhibitions * 1,220+ exhibitors * industry events * awards
- - - - - - - -
“The largest biomedical conference of its kind. SPIE BiOS, part of SPIE Photonics West, where the latest on biomedical optics, diagnostics and therapeutics, biophotonics molecular biology and genetics, optical microscopy, optical coherence tomography, and optogenetics research are presented and discussed.”
SPIE BiOS (part of SPIE Photonics West): http://spie.org/x13196.xml
http://spie.org/app/program/index.cfm?fuseaction=conferencedetail&confid=1013268
Program Tracks: http://spie.org/x7777.xml
Track: Nano/Biophotonics [ http://spie.org/x7777.xml#IDAAKPXW ]
Conference 8596 Feb4-6, “Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications” [ http://tinyurl.com/8rlkfo2 ]

2-4-2013 9-10am: Session1 - ”Molecular Probes for Targeted Imaging & Therapy
#8596-3 “Imaging of Tumor Vascular Endothelial Cells in Living Mice”
Dawen Zhao, Jason H. Stafford, Heling Zhou, Philip E. Thorpe
UTSW-MC/Dallas
ABSTRACT:
Phosphatidylserine (PS) is normally intracellular but becomes exposed on the luminal surface of vascular endothelial cells in tumors. Here we optically imaged exposed PS on tumor vasculature in vivo using PGN635, a novel human monoclonal antibody that targets PS. NIR imaging was performed after injection of IRDye800CW-PGN635 into mice bearing glioma or breast cancer. A clear tumor contrast was visible 4h later and became maximum 24h later. Fluorescence microscopy confirmed that 800CW-PGN635 was binding to PS-positive tumor vascular endothelial cells. Our studies suggest that tumor vasculature can be successfully imaged in vivo to provide sensitive tumor detection.
[Note: PGN635 is Fully-Human BAVITUXIMAB=AT004=1N11]

= = = = = = = = = = = =
M. Tumor Imaging & Dosimetry trial of I124-PGN650 (FH-Bavi) in Adv. Solid Tumors (Ph0, open-label, 1arm, n=12)
Protocol: http://clinicaltrials.gov/ct2/show/NCT01632696 (1 U.S. site as of 6-28-12)
..."I124-PGN650 is the Fab end of PS-targeting mab PGN635 (FH-Bavi) joined to the PET imaging radioisotope iodine-124, a new approach to imaging cancer."
...6-28-12: Trial added to Trials.gov, 1st site "recruiting" (Wash.UnivSM/St.Louis)
…4-3-12: Peregrine Launches PS-Targeting Clinical Imaging Pgm (AACR'12 #2452) http://tinyurl.com/7p7jovt & http://tinyurl.com/7yrwqm7
- - - - - - - - - - - - - - - - - - - - - - - -
IMAGING APPLICATIONS Of PS-TARGETING MABS:
4-3-12: Peregrine Launches PS-Targeting Clinical Imaging Program (AACR'12 #2452) http://tinyurl.com/7p7jovt & http://tinyurl.com/7yrwqm7
…PPHM "recently filed an IND" with FDA for an Imaging trial using 124I-PGN650, ~12pts.
...6-28-12: Trial added to trials.gov: http://clinicaltrials.gov/ct2/show/NCT01632696 - see CANCER TRIALS ABOVE for more details.
12-2011: Thorpe Article on FH-Bavi/Optical-Imaging in Translational Oncology http://tinyurl.com/7vcnbz2
11-14-11: Dr. Bruce Freimark presents PS IMAGING poster at AACR-NCI-EORTC Conf./SanFran http://tinyurl.com/89hpydn
9-12-11: Drs. Thorpe & Freimark present PS IMAGING posters at World Imaging Congress/S.Diego http://tinyurl.com/3uv5rgr
9-9-11: PS IMAGING potential discussed in Qtly. Conf. Call: http://tinyurl.com/3q7hzjh
4-2011/Neoplasia: Dr. Thorpe 9-pg. article on Exposed-PE/Imaging http://tinyurl.com/5uoy6fh
…Dr. Thorpe: "PE also has potential as a marker for Imaging human malignancies."
4-6-11/AACR'11: Tumor Imaging Applications of PS-Targeting Antibodies http://tinyurl.com/68p9zs4
…Steve King: "Molecular imaging is a growing field and represents an entirely new development opportunity for our first-in-class PS-targeting antibody platform… our antibodies labeled with imaging tracers hold potential for illustrating exposed PS in a clinical oncology setting, imaging PS as a companion diagnostic with bavituximab therapy, as well as ultimately assessing patient response to a range of cancer therapies."
3-14-11: Dr. Thorpe discusses PS IMAGING in Conf. Call: http://tinyurl.com/4p4hqr5
…Dr. Thorpe: "The quality of the images is quite extraordinary. The antibody homes to tumor blood vessels beautifully in all tumors that we've seen with really very, very little of a staining seen in other tissues, and that's just what you'd like to see in a diagnostic - we are looking at that very seriously. And also, that binding is correlated to response, both with radiotherapy & chemotherapy. So again, we have the possibility of making a diagnostic that would be predictive of response. We are evaluating that possibility at this time... Duramycin binds PE; binding PE expands our coverage of our broad aminophospholipid-targeting platform, so it really dovetails very beautifully with the existing antibody portfolios. It's expanding our desire to explore different phospholipids as potential targets for therapy & diagnosis… PE is phosphatidylethanolamine and it is the brother of PS. So where PE goes, so does PS and vice versa. So the 2 lipids co-segregate normally on the inside surface of the plasma membrane, but in activated cells or apoptotic cells or stress cells, both lipids flip, and both are potential targets for therapeutics or diagnostics… Duramycin is a little peptide, that's a small molecule and has quite different qualities from an antibody in terms of penetrants. So we're intrigued to see how it plays out, too."
6-24-09 U.S. Patent #7,550,141 granted: Anti-PS for Tumor Imaging: http://tinyurl.com/ln9ub8
3-3-08: Thorpe/Mason C.C.R. (AACR) article on Arsenic-labeled Bavi for Imaging Tumors: http://tinyurl.com/32jbfl
…3-5-08 Chemistry World followup article on CCR Bavi+Arsenic/IMAGING: http://tinyurl.com/4m4lbse
2006/SMI: Thorpe/Mason, "Optical Imaging of Exposed PS in Tumors" http://tinyurl.com/42nh7d9
…"We believe optical imaging with Bavituximab holds great promise for assessing PS expression, and therapeutic activity in vivo and optimizing treatment protocols."